Conference: Systems Epigenetics (hosted by Dr Pernette J. Verschure, UvA)
Amsterdam, The Netherlands
Systems Epigenetics: Towards Precision Cancer Medicine
Amsterdam Institute for Molecules, Medicines and Systems
Conference / Symposium / Seminar
From 27-30 November 2018, the international conference 'Systems Epigenetics: Towards Precision Cancer Medicine' takes place. The conference is organized in the context of the EpiPredict EU H2020 Innovative Training Network coordinated by Dr Pernette Verschure (UvA). Registration & abstracts deadline 28 May 2018. (Early bird rate: Euro 210,-).
Please read the invitation below.
We warmly invite you to join the international conference Systems Epigenetics: Towards Precision Cancer Medicine, Amsterdam, The Netherlands, 27-30 November 2018.
This conference brings together scientists from multidisciplinary fields employing different research strategies providing a platform for scientists focusing on fundamental and biomedical research, clinicians and private sector scientists. We aim to create a vibrant environment to promote cross-talk between different disciplines. We will discuss various aspects of epigenetic regulation (e.g. higher order chromatin folding, chromatin enhancer regulation, dynamics of chromatin and nuclear organization and epigenomics) in the context of cancer initiation, progression and treatment. The latest scientific developments to studying epigenetic regulation will be presented by keynote and invited speakers setting ground for precision medicine in cancer treatment. We have a great line-up of high level speakers.
On behalf of the organising committee
Dr Pernette J. Verschure (University of Amsterdam)
The Systems Epigenetics: Towards Precision Cancer Medicine Conference is organized in the context of the EpiPredict EU H2020 Innovative Training Network (www.EpiPredict.eu) coordinated by Dr Pernette Verschure. EpiPredict employs a systems medicine approach to obtain a detailed mechanistic understanding of epigenetic regulation in resistance development against hormonal treatment in breast cancer estrogen receptor positive patients.
We invite you to: